Skip Navigation LinksHome > August 1, 2014 - Volume 66 - Issue 4 > Survival After Cancer in Italian Persons With AIDS, 1986–200...
JAIDS Journal of Acquired Immune Deficiency Syndromes:
doi: 10.1097/QAI.0000000000000184
Epidemiology and Prevention

Survival After Cancer in Italian Persons With AIDS, 1986–2005: A Population-Based Estimation

Maso, Luigino Dal PhD*; Suligoi, Barbara MD; Franceschi, Silvia MD; Braga, Claudia ScD*; Buzzoni, Carlotta ScD§,‖; Polesel, Jerry ScD*; Zucchetto, Antonella ScD*,¶; Piselli, Pierluca ScD#; Falcini, Fabio MD**; Caldarella, Adele MD; Zanetti, Roberto MD††; Vercelli, Marina MD‡‡; Guzzinati, Stefano ScD§§; Russo, Antonio PhD‖‖; Tagliabue, Giovanna MD¶¶; Iachetta, Francesco MD##; Ferretti, Stefano MD***; Limina, Rosa M. MD†††; Mangone, Lucia MD‡‡‡; Michiara, Maria MD§§§; Stracci, Fabrizio MD‖‖‖; Pirino, Daniela R. MD¶¶¶; Piffer, Silvano MD###; Giacomin, Adriano MD****; Vitarelli, Susanna MD††††; Mazzoleni, Guido MD‡‡‡‡; Iannelli, Arturo BSc§§§§; Contrino, Maria L. MD‖‖‖‖; Fusco, Mario MD¶¶¶¶; Tumino, Rosario MD####; Fanetti, Anna C. PhD*****; De Paoli, Paolo MD†††††; Decarli, Adriano PhD; Serraino, Diego MD*,‡‡‡‡‡; and the Cancer and AIDS Registries Linkage Study

Supplemental Author Material
Collapse Box

Abstract

Background: Cancer survival in persons with AIDS (PWA) after introduction of antiretroviral therapies remains poorly characterized. The aim is to provide population-based estimates of cancer survival, overall and for the most important cancer types in PWA, and a comparison with persons without AIDS (non-PWA) affected by the same cancer.

Methods: PWA with cancer at AIDS diagnosis or thereafter were individually matched with non-PWA by type of cancer, sex, age, year of diagnosis, area of living, and, for lymphomas, histological subtype. Five-year observed survival and hazard ratios (HRs) of death in PWA versus non-PWA with 95% confidence intervals (CIs) were estimated.

Results: We included 2262 Italian PWA and 4602 non-PWA with cancer diagnosed during 1986–2005. Between 1986 and 1995, and 1996 and 2005, 5-year survival for all cancers in PWA improved from 12% to 41% and the corresponding HR versus non-PWA decreased from 5.1 (95% CI: 4.3 to 6.1) to 2.9 (95% CI: 2.6 to 3.3). During 1996–2005, HRs were 2.0 (95% CI: 1.4 to 2.9) for Kaposi sarcoma, 3.4 (95% CI: 2.9 to 4.1) for non-Hodgkin lymphoma, and 2.4 (95% CI: 1.4 to 4.0) for cervical cancer. HRs were 2.5 (95% CI: 2.1 to 3.1) for all non–AIDS-defining cancers, 5.9 (95% CI: 3.1 to 11.2) for Hodgkin lymphoma, and 7.3 (95% CI: 2.8 to 19.2) for nonmelanoma skin cancer. A ≤3-fold survival difference was found for cancers of the stomach, liver, anus, lung, brain, and the most aggressive lymphoma subtypes.

Conclusions: The persisting, although narrowing, gap in cancer survival between PWA and non-PWA indicates the necessity of enhancing therapeutic approaches, so that PWA can be provided the same chances of survival observed in the general population, and improving cancer prevention and screening.

© 2014 by Lippincott Williams & Wilkins

Login

Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.